Chronic wound management remains a significant challenge for patients undergoing oral anticoagulant therapy. Healthcare providers often worry about the effectiveness of blood-derived treatments in these individuals. Recently, an exploratory ex vivo study investigated the success of ActiGraft clot formation in patients receiving medications like warfarin and rivaroxaban. The findings provide crucial insights into how these anticoagulants influence the development of autologous whole blood clots.

The research stratified twenty-five participants into three distinct cohorts based on their treatment regimen. These groups included a vitamin K antagonist group (warfarin), a factor Xa inhibitor group (rivaroxaban), and a healthy control group. Specifically, the researchers measured the clot formation time (CFT). They defined this as the point where fluid movement stopped. While the anticoagulant groups showed longer formation times than the controls, the results remained within the standard reference range of 8 to 12 minutes.

Optimizing ActiGraft Clot Formation in Clinical Practice

Consequently, the study confirms that ActiGraft technology is feasible for patients on systemic anticoagulation. Moreover, the results indicated no statistically significant difference between patients taking warfarin and those on rivaroxaban. This is particularly relevant for Indian clinicians managing elderly patients with multiple comorbidities. Therefore, doctors can confidently apply this autologous therapy without needing to pause essential anticoagulant medications.

In addition, the average clot formation time for the entire study population was approximately 10.5 minutes. Notably, the study demonstrates that the proprietary coagulation process in ActiGraft overcomes the inhibitory effects of oral anticoagulants. Furthermore, this approach provides a bioactive scaffold that supports natural healing. As a result, the therapy remains a viable option for high-risk patients with chronic lower limb ulcers.

Frequently Asked Questions

Does warfarin interfere with ActiGraft clot formation?

Research shows that while warfarin may slightly increase the time it takes for a clot to form, the process still occurs within the clinically acceptable range of 8 to 12 minutes.

Can patients on rivaroxaban use ActiGraft for wound healing?

Yes, the study confirmed that patients on factor Xa inhibitors like rivaroxaban can successfully form autologous clots using the ActiGraft system, making it a feasible option for wound care.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Jacobson BF et al. Autologous whole blood clot formation with actigraft in patients receiving oral anticoagulant therapy: an ex vivo feasibility study. J Thromb Thrombolysis. 2026 May 24. doi: 10.1007/s11239-026-03321-4. PMID: 42177743.

Snyder RJ, et al. A prospective, randomized, multicenter, controlled trial of an autologous whole blood clot product in the treatment of diabetic foot ulcers. Wounds. 2024.

RedDress Ltd. ActiGraft Pro: Personalized Care for Chronic Wounds. Woundsource.com. 2024.